-
1.发明申请5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR 审中-公开5-5-共聚合的杂环化合物及其作为HCV聚合酶抑制剂的用途公开(公告)号：US20120020920A1
公开(公告)日：2012-01-26
申请号：US13034306
申请日：2011-02-24
申请人： Ryo Mizojiri , Shintaro Hirashima , Takahiro Oka , Kenta Aoki , Satoru Noji , Izuru Ando , Toshihiro Sato , Yasushi Niwa
发明人： Ryo Mizojiri , Shintaro Hirashima , Takahiro Oka , Kenta Aoki , Satoru Noji , Izuru Ando , Toshihiro Sato , Yasushi Niwa
IPC分类号： A61K38/21 , A61K31/4188 , A61K31/407 , A61P1/16 , A61K31/496 , A61K31/454 , A61K31/4545 , A61P31/14 , C07D495/04 , A61K31/5377
CPC分类号： C07D495/04
摘要： The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
摘要翻译： 本发明涉及由下式[I]表示的稠环化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。
-
2.发明授权公开(公告)号：US07659263B2
公开(公告)日：2010-02-09
申请号：US11271136
申请日：2005-11-10
申请人： Ryo Mizojiri , Takahiro Oka , Kenta Aoki , Satoru Noji , Yoko Matsumoto , Toshihiro Sato , Izuru Ando , Yasushi Niwa
发明人： Ryo Mizojiri , Takahiro Oka , Kenta Aoki , Satoru Noji , Yoko Matsumoto , Toshihiro Sato , Izuru Ando , Yasushi Niwa
IPC分类号： A61P1/16 , A61P31/12 , A61P43/00 , A61K31/553 , A61K31/5517 , C07D498/12 , C07D267/02 , C07D495/14
CPC分类号： C07D498/14 , A61K31/5517 , A61K31/553 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
摘要翻译： 本发明涉及由下式[I]表示的噻吩并吡咯化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和肝炎治疗剂 C含有该化合物作为活性成分。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。
-
3.发明申请5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor 审中-公开5-5-稠合杂环化合物及其作为HCV聚合酶抑制剂的用途公开(公告)号：US20090036444A1
公开(公告)日：2009-02-05
申请号：US11436375
申请日：2006-05-18
申请人： Ryo Mizojiri , Shintaro Hirashima , Takahiro Oka , Kenta Aoki , Satoru Noji , Izuru Ando , Toshihiro Sato , Yasushi Niwa
发明人： Ryo Mizojiri , Shintaro Hirashima , Takahiro Oka , Kenta Aoki , Satoru Noji , Izuru Ando , Toshihiro Sato , Yasushi Niwa
IPC分类号： A61K31/5377 , C07D235/02 , A61K31/4188 , C07D495/02 , A61K31/496 , A61K31/454 , A61P31/12 , A61K31/4545 , C07D211/00 , C07D241/02 , A61K31/407 , C07D295/00
CPC分类号： C07D495/04
摘要： The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
摘要翻译： 本发明涉及由下式[I]表示的稠环化合物，其中每个符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和治疗剂 含有该化合物的丙型肝炎。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。
-
公开(公告)号：US08703758B2
公开(公告)日：2014-04-22
申请号：US13094015
申请日：2011-04-26
申请人： Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
发明人： Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
IPC分类号： A01N43/00 , A61K31/00 , A01N43/42 , A61K31/44 , A01N43/76 , A61K31/42 , A01N43/56 , A61K31/415 , A01N43/08 , A61K31/34 , C07D413/14 , C07D405/02 , C07D401/02 , C07D401/14 , C07D403/02 , C07D491/048 , A61K31/41 , A61K31/439 , A61K31/444 , A61K31/4439
CPC分类号： C07D413/14 , A61K31/41 , A61K31/415 , A61K31/439 , A61K31/4439 , A61K31/444 , C07D231/54 , C07D263/56 , C07D263/58 , C07D307/81 , C07D401/02 , C07D401/14 , C07D403/02 , C07D405/02 , C07D413/04 , C07D417/04 , C07D487/08 , C07D491/048 , C07D498/04
摘要： The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
摘要翻译： 本发明提供具有ACC抑制作用的化合物，其可用作预防或治疗肥胖症，糖尿病，高血压，高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症，癌症等的药剂，以及 具有优越的疗效。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。
-
公开(公告)号：US20120142714A1
公开(公告)日：2012-06-07
申请号：US13306069
申请日：2011-11-29
申请人： TSUNEO YASUMA , MAKOTO KAMATA , TOHRU YAMASHITA , HIDEKI HIROSE , MASATAKA MURAKAMI , ASATO KINA , KAZUKO YONEMORI , RYO MIZOJIRI , IKUO FUJIMORI , TAKUYA FUJIMOTO , ZENICHI IKEDA
发明人： TSUNEO YASUMA , MAKOTO KAMATA , TOHRU YAMASHITA , HIDEKI HIROSE , MASATAKA MURAKAMI , ASATO KINA , KAZUKO YONEMORI , RYO MIZOJIRI , IKUO FUJIMORI , TAKUYA FUJIMOTO , ZENICHI IKEDA
IPC分类号： A61K31/4439 , A61K31/506 , A61P3/10 , A61K31/416 , A61P3/04 , C07D413/04 , C07D231/54
CPC分类号： C07D413/04 , C07D401/04 , C07D405/04 , C07D417/04
摘要： The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
摘要翻译： 本发明提供具有ACC抑制作用的化合物，其可用作预防或治疗肥胖症，糖尿病等并且具有优异的疗效。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。
-
公开(公告)号：US07803801B2
公开(公告)日：2010-09-28
申请号：US11363563
申请日：2006-02-28
申请人： Yoshitoshi Kodama , Satoru Noji , Katsuaki Imamura , Ryo Mizojiri , Kenta Aoki , Hideo Takagi , Yuichi Naka , Goro Ito , Kiyotaka Shinoda , Akihito Fujiwara , Kazunori Kurihara , Masaru Tanaka
发明人： Yoshitoshi Kodama , Satoru Noji , Katsuaki Imamura , Ryo Mizojiri , Kenta Aoki , Hideo Takagi , Yuichi Naka , Goro Ito , Kiyotaka Shinoda , Akihito Fujiwara , Kazunori Kurihara , Masaru Tanaka
IPC分类号： C07D401/00 , A61K31/47
CPC分类号： C07D417/14
摘要： The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(═O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
摘要翻译： 本发明涉及由以下通式（I）表示的氨基吡啶化合物或其盐和含有该化合物或其盐作为有效成分的Syk抑制剂。 这里，X1，X2，X3，Z，Y1，Y2表示碳原子或氮原子，R，R1，R5，R6表示氢原子，烷基等，R7表示氢原子，卤素 原子，硝基，氰基，-CpH2（p-1）（Ra1）（Ra2）-O-Ra3，-C（= O）-Rd1，5或6元饱和杂环基，芳香族 杂环基，-N（Rh1）（Rh2）等。本发明的氨基吡啶化合物不仅具有高的Syk抑制活性，而且具有选择性抑制Syk的性质。
-
公开(公告)号：US20110263562A1
公开(公告)日：2011-10-27
申请号：US13094015
申请日：2011-04-26
申请人： Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
发明人： Tohru Yamashita , Makoto Kamata , Hideki Hirose , Masataka Murakami , Takuya Fujimoto , Zenichi Ikeda , Tsuneo Yasuma , Ikuo Fujimori , Ryo Mizojiri , Tomoya Yukawa
IPC分类号： A61K31/423 , A61K31/438 , A61K31/439 , C07D417/04 , A61K31/454 , A61K31/416 , A61K31/34 , C07D498/04 , C07D413/14 , C07D413/04 , C07D263/56 , C07D231/56 , C07D307/87 , A61P35/04 , A61P3/04 , A61P3/06 , A61P9/12 , A61P9/00 , A61P3/10 , A61P3/00 , A61K31/497
CPC分类号： C07D413/14 , A61K31/41 , A61K31/415 , A61K31/439 , A61K31/4439 , A61K31/444 , C07D231/54 , C07D263/56 , C07D263/58 , C07D307/81 , C07D401/02 , C07D401/14 , C07D403/02 , C07D405/02 , C07D413/04 , C07D417/04 , C07D487/08 , C07D491/048 , C07D498/04
摘要： The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
摘要翻译： 本发明提供具有ACC抑制作用的化合物，其可用作预防或治疗肥胖症，糖尿病，高血压，高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症，癌症等的药剂，以及 具有优越的疗效。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。
-
公开(公告)号：US20060205731A1
公开(公告)日：2006-09-14
申请号：US11363563
申请日：2006-02-28
申请人： Yoshitoshi Kodama , Satoru Noji , Katsuaki Imamura , Ryo Mizojiri , Kenta Aoki , Hideo Takagi , Yuichi Naka , Goro Ito , Kiyotaka Shinoda , Akihito Fujiwara , Kazunori Kurihara , Masaru Tanaka
发明人： Yoshitoshi Kodama , Satoru Noji , Katsuaki Imamura , Ryo Mizojiri , Kenta Aoki , Hideo Takagi , Yuichi Naka , Goro Ito , Kiyotaka Shinoda , Akihito Fujiwara , Kazunori Kurihara , Masaru Tanaka
IPC分类号： A61K31/506 , A61K31/497 , A61K31/501 , A61K31/444 , C07D417/14
CPC分类号： C07D417/14
摘要： The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(═O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
摘要翻译： 本发明涉及由以下通式（I）表示的氨基吡啶化合物或其盐和含有该化合物或其盐作为有效成分的Syk抑制剂。 这里，X 1，X 2，X 3，Z，Y 1，Y 2， / SUP>表示碳原子或氮原子，R 1，R 1，R 5，R 6表示氢原子，烷基 基团等，R 7表示氢原子，卤素原子，硝基，氰基，-C 2 H 2 H（H） （R a1）（R a2） - 或 - a3 - ， - （ - O - ） - 5或6元饱和杂环基，芳香族杂环基，-N（R h1H1）（R h2H2）等。 本发明的氨基吡啶化合物不仅具有高Syk抑制活性，而且具有选择性抑制Syk的性质。
-
9.发明申请公开(公告)号：US20060167246A1
公开(公告)日：2006-07-27
申请号：US11271136
申请日：2005-11-10
申请人： Ryo Mizojiri , Takahiro Oka , Kenta Aoki , Satoru Noji , Yoko Matsumoto , Toshihiro Sato , Izuru Ando , Yasushi Niwa
发明人： Ryo Mizojiri , Takahiro Oka , Kenta Aoki , Satoru Noji , Yoko Matsumoto , Toshihiro Sato , Izuru Ando , Yasushi Niwa
IPC分类号： A61K31/553 , A61K31/551 , C07D498/14
CPC分类号： C07D498/14 , A61K31/5517 , A61K31/553 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
摘要翻译： 本发明涉及由下式[I]表示的噻吩并吡咯化合物，其中各符号如说明书中所定义，或其药学上可接受的盐，丙型肝炎病毒（HCV）聚合酶抑制剂和肝炎治疗剂 C含有该化合物作为活性成分。 本发明化合物基于HCV聚合酶抑制活性显示抗HCV活性，可用作预防或治疗丙型肝炎的药剂。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.037 秒)
